1-Methyl-2-iodmethyl-pyrrolidin | 5831-74-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-Methyl-2-iodmethyl-pyrrolidin
• 英文别名: 2-iodomethyl-1-methyl-pyrrolidine；2-(iodomethyl)-1-methylpyrrolidine
• CAS: 5831-74-3
• 化学式: C₆H₁₂IN
• 分子量: 225.072
• InChiKey: SFMBCWMRPYQHDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
  申请人：PRINCIPIA BIOPHARMA, INC.

  公开号：EP3181567A1

  公开（公告）日：2017-06-21

  The present disclosure provides compounds of Formula (II) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

  本公开提供的式(II)化合物和/或其药学上可接受的盐是酪氨酸激酶抑制剂，特别是BTK抑制剂，可用于治疗可通过抑制酪氨酸激酶治疗的疾病，如癌症、关节炎等炎症性疾病。此外，还提供了含有此类化合物和/或其药学上可接受的盐的药物组合物，以及制备此类化合物及其药学上可接受的盐的工艺。
• Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors
  申请人：Orion Corporation

  公开号：US10336697B2

  公开（公告）日：2019-07-02

  The present invention provides novel spiro[cyclobutane-1,3′-indolin]-2′-one derivatives of formula (I) in which Cy, R1, R2, R4, L, and m have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.

  本发明提供了式 (I) 的新型螺[环丁烷-1,3′-吲哚啉]-2′-酮衍生物 其中 Cy、R1、R2、R4、L 和 m 具有说明书中给出的含义，以及它们的药学上可接受的盐。式（I）化合物可作为溴链抑制剂用于治疗或预防需要溴链抑制的疾病或失调。
• SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS
  申请人：Orion Corporation

  公开号：US20180186739A1

  公开（公告）日：2018-07-05

  The present invention provides novel spiro[cyclobutane-1,3′-indolin]-2′-one derivatives of formula (I) in which Cy, R 1 , R 2 , R 4 , L, and m have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.